Do analysts recommend UPC or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, UPC or RFL?

Universe Pharmaceuticals has higher revenue and earnings than Rafael. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.74M 1.51 -$3.67M N/A N/A Rafael $920K 134.52 -$30.52M -$0.68 N/A

Do analysts recommend FBIO or UPC?

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 493.37%. Given Fortress Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Fortress Biotech is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, FBIO or UPC?

Fortress Biotech has higher revenue and earnings than Universe Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortress Biotech $63.26M 1.51 $6.82M $2.64 1.09 Universe Pharmaceuticals $17.74M 1.51 -$3.67M N/A N/A

Do analysts recommend CGTX or UPC?

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 215.96%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, CGTX or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Cognition Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A Universe Pharmaceuticals $17.74M 1.51 -$3.67M N/A N/A

Is CGTX or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Universe Pharmaceuticals N/A N/A N/A

Do analysts rate UPC or ALDX?

Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 255.99%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, UPC or ALDX?

Universe Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.74M 1.51 -$3.67M N/A N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A

Is UPC or ALDX more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Aldeyra Therapeutics N/A -53.14% -34.94%

Do analysts prefer UPC or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, UPC or ICCC?

ImmuCell has higher revenue and earnings than Universe Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.74M 1.51 -$3.67M N/A N/A ImmuCell $27.64M 3.31 -$1.04M $0.08 126.00

Universe Pharmaceuticals (UPC) Competitors

$5.33 +0.01 (+0.24%)

As of 10:31 AM Eastern

Compare

UPC vs. RFL, FBIO, CGTX, ALDX, and ICCC

Should you buy Universe Pharmaceuticals stock or one of its competitors? Universe Pharmaceuticals's main competitors and comparable companies include Rafael (RFL), Fortress Biotech (FBIO), Cognition Therapeutics (CGTX), Aldeyra Therapeutics (ALDX), and ImmuCell (ICCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Universe Pharmaceuticals compare to Rafael?

Universe Pharmaceuticals (NASDAQ:UPC) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Universe Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Universe Pharmaceuticals has higher revenue and earnings than Rafael.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.74M	1.51	-$3.67M	N/A	N/A
Rafael	$920K	134.52	-$30.52M	-$0.68	N/A

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Rafael. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 1 mentions for Rafael. Rafael's average media sentiment score of 0.67 beat Universe Pharmaceuticals' score of 0.44 indicating that Rafael is being referred to more favorably in the news media.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Rafael	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Universe Pharmaceuticals' return on equity of 0.00% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Rafael	-3,321.74%	-41.27%	-35.32%

Summary

Universe Pharmaceuticals beats Rafael on 8 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Fortress Biotech had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Universe Pharmaceuticals. Fortress Biotech's average media sentiment score of 0.85 beat Universe Pharmaceuticals' score of 0.44 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Fortress Biotech	Positive
Universe Pharmaceuticals	Neutral

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 493.37%. Given Fortress Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Fortress Biotech is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Fortress Biotech has higher revenue and earnings than Universe Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.51	$6.82M	$2.64	1.09
Universe Pharmaceuticals	$17.74M	1.51	-$3.67M	N/A	N/A

Fortress Biotech has a net margin of 163.32% compared to Universe Pharmaceuticals' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Universe Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Universe Pharmaceuticals	N/A	N/A	N/A

Summary

Fortress Biotech beats Universe Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Universe Pharmaceuticals' return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Universe Pharmaceuticals	N/A	N/A	N/A

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 215.96%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 2 articles in the media. Cognition Therapeutics' average media sentiment score of 1.61 beat Universe Pharmaceuticals' score of 0.44 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Very Positive
Universe Pharmaceuticals	Neutral

Universe Pharmaceuticals has higher revenue and earnings than Cognition Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Universe Pharmaceuticals	$17.74M	1.51	-$3.67M	N/A	N/A

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cognition Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Summary

Cognition Therapeutics beats Universe Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Aldeyra Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 2 mentions for Universe Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Universe Pharmaceuticals' score of 0.44 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Aldeyra Therapeutics	Positive

Universe Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.74M	1.51	-$3.67M	N/A	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Universe Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 255.99%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Universe Pharmaceuticals and Aldeyra Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to ImmuCell?

Universe Pharmaceuticals (NASDAQ:UPC) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Universe Pharmaceuticals and Universe Pharmaceuticals both had 2 articles in the media. ImmuCell's average media sentiment score of 0.94 beat Universe Pharmaceuticals' score of 0.44 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
ImmuCell	Positive

Universe Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ImmuCell has higher revenue and earnings than Universe Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.74M	1.51	-$3.67M	N/A	N/A
ImmuCell	$27.64M	3.31	-$1.04M	$0.08	126.00

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has a net margin of 2.57% compared to Universe Pharmaceuticals' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Universe Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
ImmuCell	2.57%	2.69%	1.76%

Summary

ImmuCell beats Universe Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPC vs. The Competition

Export

Metric	Universe Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26.75M	$12.24B	$7.23B	$12.87B
Dividend Yield	N/A	2.61%	2.54%	11.02%
P/E Ratio	N/A	780.49	272.48	24.29
Price / Sales	1.51	791.27	608.54	79.97
Price / Cash	N/A	96.46	79.89	53.65
Price / Book	0.05	12.02	13.12	6.25
Net Income	-$3.67M	$2.82B	$3.47B	$348.11M
7 Day Performance	0.06%	2.00%	2.05%	1.47%
1 Month Performance	54.58%	5.81%	8.25%	4.70%
1 Year Performance	44.92%	7.24%	26.26%	17.01%

Universe Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0.5496 of 5 stars	$5.33 +0.2%	N/A	+41.1%	$26.75M	$17.74M	N/A	220	Short Interest Increase Gap Down
RFL Rafael	0.2571 of 5 stars	$1.87 -6.0%	N/A	+50.5%	$103.48M	$920K	N/A	20	Analyst Forecast
FBIO Fortress Biotech	3.1822 of 5 stars	$2.82 -3.8%	$17.00 +502.8%	+19.6%	$97.33M	$63.26M	1.07	170
CGTX Cognition Therapeutics	2.8971 of 5 stars	$1.02 +1.0%	$3.33 +226.8%	-63.3%	$96.04M	N/A	N/A	20	Positive News
ALDX Aldeyra Therapeutics	3.3829 of 5 stars	$1.56 flat	$5.50 +252.6%	-73.5%	$94.11M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Universe Pharmaceuticals (UPC) Competitors

UPC vs. RFL, FBIO, CGTX, ALDX, and ICCC

How does Universe Pharmaceuticals compare to Rafael?

Summary

How does Universe Pharmaceuticals compare to Fortress Biotech?

Summary

How does Universe Pharmaceuticals compare to Cognition Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Aldeyra Therapeutics?

Summary

How does Universe Pharmaceuticals compare to ImmuCell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Universe Pharmaceuticals (UPC) Competitors

UPC vs. RFL, FBIO, CGTX, ALDX, and ICCC

How does Universe Pharmaceuticals compare to Rafael?

Which has more volatility & risk, UPC or RFL?

Which has stronger valuation & earnings, UPC or RFL?

Do insiders & institutionals believe in UPC or RFL?

Does the media favor UPC or RFL?

Do analysts recommend UPC or RFL?

Is UPC or RFL more profitable?

Summary

How does Universe Pharmaceuticals compare to Fortress Biotech?

Which has more risk and volatility, FBIO or UPC?

Does the media prefer FBIO or UPC?

Do analysts recommend FBIO or UPC?

Do insiders and institutionals hold more shares of FBIO or UPC?

Which has preferable valuation & earnings, FBIO or UPC?

Is FBIO or UPC more profitable?

Summary

How does Universe Pharmaceuticals compare to Cognition Therapeutics?

Is CGTX or UPC more profitable?

Do analysts recommend CGTX or UPC?

Does the media refer more to CGTX or UPC?

Which has preferable earnings & valuation, CGTX or UPC?

Do institutionals and insiders believe in CGTX or UPC?

Which has more volatility & risk, CGTX or UPC?

Summary

How does Universe Pharmaceuticals compare to Aldeyra Therapeutics?

Does the media favor UPC or ALDX?

Which has stronger earnings and valuation, UPC or ALDX?

Which has more volatility & risk, UPC or ALDX?

Do institutionals & insiders have more ownership in UPC or ALDX?

Is UPC or ALDX more profitable?

Do analysts rate UPC or ALDX?

Summary

How does Universe Pharmaceuticals compare to ImmuCell?

Does the media favor UPC or ICCC?

Which has more volatility & risk, UPC or ICCC?

Do institutionals and insiders have more ownership in UPC or ICCC?

Which has stronger earnings & valuation, UPC or ICCC?

Do analysts prefer UPC or ICCC?

Is UPC or ICCC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools